Canada

#Antibody-based therapeutics #Canada #Non-animal model (NAM)

Canadian companies to partner on novel antibody therapies 

VoxCell BioInnovation and adMare BioInnovations have announced a research partnership to advance novel antibody therapies in non-animal models.  VoxCell says its human-relevant vascularised tissue platform brings together human tumour, immune, and stromal compartments alongside a perfused, endothelial-lined vasculature in a single bioprinted construct.   The result is a… Read More

#News

#Canada #Fujifilm #Japan

Collaboration to advance AAV production enhancers 

A Canadian Japanese co-innovation programme is set to advance AAV production enhancers.  AAV vectors are a cornerstone of in vivo gene delivery for gene therapies, but they remain difficult and expensive to manufacture at scale. As pipelines expand to more indications and broader patient populations, significantly greater amounts of… Read More

#News

T cells attack a cancer cell
#Anti-inflammatory #Canada #GPCRs #Immuno-oncology

Kainova secures funding to develop GPCR-targeting therapies 

Biopharmaceutical company Kainova Therapeutics has secured $32 million CAD (US $24 million) to accelerate the development of immuno-oncology and inflammation therapies.  This financing round was led by Investissement Québec, with funds set to support Kainova’s advancement of GPCR-targeting therapies.  The company’s lead asset DT-7012, a Treg-depleting anti-CCR8 antibody,… Read More

#Business & Investment #News

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

DDW Highlights: 27 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More

#Podcasts

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

This week in Drug Discovery (19 – 23 January) 

News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology.  The top stories:    Combination therapy could slash melanoma mortality… Read More

#News

#Biology #Biotech #Canada

VoxCell appoints Graham Craig as COO 

Canadian biotechnology company VoxCell has appointed Graham Craig as Chief Commercial Officer (COO).  Craig joins VoxCell from clinical-stage biotechnology company AbCellera with experience in commercialisation and strategic partnerships across the pharmaceutical and biotech sectors. Craig will lead VoxCell’s commercial strategy, including global business development, strategic partnerships, and go-to-market execution as the industry accelerates adoption of… Read More

#News

Clinical trial
#Canada #UK #Vaccines

UK-Canadian partnership to advance vaccine technology 

A £750,000 ($1 million) global collaboration has been launched to advance next-generation vaccine technology.  iiDiagnostics (iiDX), a company formed by the Infection Innovation Consortium: iiCON, and Canadian biotech Eyam Health have launched a collaboration to bring forward Eyam Health’s novel vaccine technology using advanced automated organoid models.   This £750,000… Read More

#Business & Investment #News